Pancreatic Cancer Clinical Trials

Find Pancreatic Cancer Clinical Trials Near You

Research of the Application of Pancreatic Cancer Screening Artificial Intelligence Model 'PANDAPro': A Single-Center,Realworld Clinical Trial

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The purpose of this study is to build upon the previously developed deep learning-based non-contrast CT pancreatic cancer screening model, PANDA. The model will first undergo training and enhancement, followed by external validation across multiple centers. Subsequently, a large-scale real-world validation will be conducted at Zhejiang University's First Affiliated Hospital , the study will be divided into two rounds. In the first round, the performance of the PANDA model and the upgraded PANDA Pro model will be compared on consecutive retrospective real-world CT scans. In the second round, physicians will record the PANDA Pro results in real time to identify potential pancreatic lesions that may have been clinically missed. By leveraging clinical big data across different scenarios at Zhejiang University's First Affiliated Hospital, the study aims to validate the model's role in prompting and supplementing the diagnosis of PDAC in clinical practice, thereby laying the foundation for large-scale opportunistic screening of PDAC.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 90
Healthy Volunteers: t
View:

• Subjects who have undergone chest and/or abdominal CT scans at outpatient clinics, inpatient departments, or physical examination centers;

• Age at the time of the scan between 18-90 years old, with no restriction on gender;

Locations
Other Locations
China
the First Affiliated Hospital, School of Medicine, Zhejiang University
RECRUITING
Hangzhou
Contact Information
Primary
Qi Zhang
qi.zhang@zju.edu.cn
13819137113
Time Frame
Start Date: 2025-11-18
Estimated Completion Date: 2027-08-01
Participants
Target number of participants: 100000
Treatments
Experimental: PANDA Pro
recall of clinically missed but PANDA Pro detected pancreatic lesions
Related Therapeutic Areas
Sponsors
Collaborators: Lishui Municipal Central Hospital, Second Affiliated Hospital of Nanchang University
Leads: Zhejiang University

This content was sourced from clinicaltrials.gov